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Neurobiology of Disease
Oligodendroglial TNFR2Mediates Membrane TNF-
Dependent Repair in Experimental Autoimmune
Encephalomyelitis by Promoting Oligodendrocyte
Differentiation and Remyelination
Pernille M. Madsen,1,2 Dario Motti,3 Shaffiat Karmally,1 David E. Szymkowski,4 Kate Lykke Lambertsen,2
John R. Bethea,5 and Roberta Brambilla1
1The Miami Project To Cure Paralysis, University of Miami Miller School of Medicine, Miami, Florida 33136, 2Department of Neurobiology Research,
Institute of Molecular Medicine, University of Southern Denmark, 5230 Odense, Denmark, 3Nationwide Children’s Hospital, Columbus, Ohio 43205,
4Xencor Inc., Monrovia, California 91016, and 5Department of Biology, Drexel University, Philadelphia, Pennsylvania 19104
Tumornecrosis factor (TNF) is associatedwith thepathophysiologyof variousneurological disorders, includingmultiple sclerosis. It exists as a
transmembrane form tmTNF, signaling via TNF receptor 2 (TNFR2) and TNFR1, and a soluble form, solTNF, signaling via TNFR1. Multiple
sclerosis is associatedwith the detrimental effects of solTNF acting throughTNFR1,while tmTNFpromotes repair and remyelination.Herewe
demonstrate that oligodendroglial TNFR2 is a keymediator of tmTNF-dependent protection in experimental autoimmune encephalomyelitis
(EAE). CNP-cre:TNFR2fl/fl mice with TNFR2 ablation in oligodendrocytes show exacerbation of the disease with increased axon and myelin
pathology, reduced remyelination, and increased loss of oligodendrocyte precursor cells and mature oligodendrocytes. The clinical course of
EAE is not improved by the solTNF inhibitor XPro1595 in CNP-cre:TNFR2fl/fl mice, indicating that for tmTNF to promote recovery TNFR2 in
oligodendrocytes is required.We show that TNFR2 drives differentiation of oligodendrocyte precursor cells, but not proliferation or survival.
TNFR2ablation leads todysregulated expressionofmicroRNAs, amongwhichare regulators of oligodendrocytedifferentiationand inflamma-
tion, including miR-7a. Our data provide the first direct in vivo evidence that TNFR2 in oligodendrocytes is important for oligodendrocyte
differentiation, thereby sustaining tmTNF-dependent repair in neuroimmune disease. Our studies identify TNFR2 in the CNS as a molecular
target for the development of remyelinating agents, addressing themost pressing need inmultiple sclerosis therapy nowadays.
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Introduction
Multiple sclerosis (MS) is themost common neurological disease
in young adults. Despite the general consensus on the autoim-
mune component of MS, its etiology remains unknown. Current
treatments can slow disease progression, reduce relapses, and
improve quality of life, but are not effective in halting or reverting
myelin and axon damage, which are causes of permanent disabil-
ity. To address the need for long-term reparative therapies, new
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Significance Statement
Our study, using novel TNF receptor 2 (TNFR2) conditional KOmice with selective TNFR2 ablation in oligodendrocytes, provides
the first direct evidence that TNFR2 is an important signal for oligodendrocyte differentiation. Following activationby transmem-
brane TNF, TNFR2 initiates pathways that drive oligodendrocytes into a reparativemode contributing to remyelination following
disease. This identifies TNFR2 as a newmolecular target for the development of therapeutic agents in multiple sclerosis.
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pharmacological targets must be identified by elucidating the
mechanisms of the underlying neurodegenerative process.
Tumor necrosis factor (TNF) is an immunomodulatory cyto-
kine regulating physiological and pathological processes. TNF
exists in two forms, transmembrane TNF (tmTNF) and soluble
TNF (solTNF). solTNF derives from the cleavage of tmTNF by
the TNF- converting enzyme (Kriegler et al., 1988). The cellular
functions of TNF are mediated by TNF receptor 1 (TNFR1) and
TNFR2, which differ in expression, ligand affinity, structure, and
downstream signaling pathways. solTNF and tmTNF can bind to
both receptors but with different affinities. As a result, solTNF
signals only through TNFR1 mediating primarily inflammation
and apoptosis (Holtmann andNeurath, 2004), while tmTNF sig-
nals through both TNFR1 and TNFR2, promoting cell survival,
resolution of inflammation, immunity and myelination (Grell et
al., 1995; Probert, 2015).
TNF has been linked to MS pathophysiology (McCoy and Tan-
sey, 2008).MSpatientshavehighconcentrationsof solTNF inserum
and CSF (Maimone et al., 1991; Sharief and Hentges, 1991), and
markedTNF immunoreactivitywithin active lesions (Hofmanet al.,
1989; Selmaj et al., 1991). In experimentalmodels ofMS, TNFover-
expression causes demyelination (Probert et al., 1995; Akassoglou et
al., 1998; Dal Canto et al., 1999), while blockade improves the out-
come (Ruddle et al., 1990; Baker et al., 1994). Nevertheless, the only
MSclinical trialwith anonselectiveTNF inhibitor, Lenercept, had to
be terminateddue tooccurrences of demyelination (LenerceptMul-
tiple Sclerosis StudyGroup andUniversity of British ColumbiaMS/
MRI Analysis Group, 1999). Subsequent studies in knock-out (KO)
mice uncovered that the two forms of TNF and their receptors have
opposing biologic effects. Ablation of TNF or TNFR1/TNFR2 com-
bined did not protect from experimental autoimmune encephalo-
myelitis (EAE), rather it caused exacerbation of chronic disease
(Ko¨rner et al., 1997; Liu et al., 1998; Eugster et al., 1999; Kassiotis et
al., 1999; Suvannavejh et al., 2000). TNFR1 ablation resulted in less
severe EAE and better remyelination, while TNFR2 ablation caused
worse EAE and prevented remyelination (Liu et al., 1998; Eugster et
al., 1999; Suvannavejh et al., 2000; Arnett et al., 2001). Furthermore,
mice only expressing tmTNF showed suppression of EAE (Alexo-
poulou et al., 2006). Based on these studies, the understanding of
TNF involvement inMShas evolved, and a dichotomy has emerged
between solTNF and tmTNF: MS and EAE are associated with the
detrimental effects of solTNFviaTNFR1,while tmTNF is important
for repair and remyelination via TNFR2. In our own studies, we
demonstrated that selective blockade of solTNFwith XPro1595 im-
proved EAE outcome, while the inhibition of both TNF forms with
etanercept exacerbated the disease (Brambilla et al., 2011). The ther-
apeutic effect of XPro1595 was associated with axon preservation,
improved myelin compaction, and increased remyelination, sug-
gesting that tmTNF might have protective functions by acting di-
rectly on cells of the oligodendrocyte lineage, which we showed
express high levels of the tmTNF-responsive receptor TNFR2. To
address this hypothesis, we generated oligodendrocyte-specific
TNFR2 conditional KO mice (CNP-cre:TNFR2fl/fl mice). CNP-
cre:TNFR2fl/flmice exhibitmore severe EAE,which is not improved
by XPro1595 treatment, indicating that oligodendroglial TNFR2 is
required for tmTNF beneficial functions. We show that, without
TNFR2, oligodendrocyte differentiation is impaired and microRNAs
(miRNAs) known to be crucial signals in regulating this process
(miR-219,miR-138,miR-338,miR-7a) are dysregulated. Our study
demonstrates that TNF signaling via TNFR2 has important repair
functions in demyelinating disease by directly promoting oligoden-
drocyte differentiation. This has significant implications, particu-
larly for thechronicprogressive formofMS, forwhichnotreatments
are available. EnhancingTNFR2 signaling in theCNSmayprovide a
viable therapeutic option toboost remyelination andachieveneuro-
protection, halting, or even reverting, the progression of the disease.
Materials andMethods
Mice
Adult, age-matched (2–4months of age) female andmalemicewere used in
this study: males for all behavioral assessments in naive conditions, females
for all EAE experiments, as they develop amore reproducible disease clinical
course. All mouse lines were on a C57BL/6 background, since this genetic
background develops a chronic nonrelapsing form of disease when used in
myelin oligodendrocyte glycoprotein 35–55 peptide (MOG35–55)-induced
EAE (Rangachari and Kuchroo, 2013). TNFR2fl/fl mice were obtained by
breeding C57BL/6NTac-Tnfrsf1b tm1a(EUCOMM)Wtsi/Ics mice (European
MouseMutantArchive, EUCOMMConsortium)with anFLPdeleter strain
(catalog #009086, The Jackson Laboratory) to remove the FRT (FLP recom-
binase target)-flanked neomycin cassette. CNP-cre/mice (Lappe-Siefke
et al., 2003)were a gift fromDr. KlausNave (Max Planck Institute of Exper-
imentalMedicine, Gottingen, Germany). TNFR2fl/fl andCNP-cre/mice
were bred to generate CNP-cre:TNFR2fl/fl conditional KOs. TNFR2fl and
TNFR2WT alleles were genotyped with the following primers: forward, 5
TTGGGTCTAGAGGTGGCGCAGC 3; and reverse, 5 GGCCAG
GAAGTGGGTTACTTTAGGGC 3. TNFR2/ (catalog #002620), WT
C57BL/6, and Rosa26-stop-EYFP mice (catalog #006148) were obtained
from The Jackson Laboratory. Colonies were housed in the Animal Core
Facility of TheMiamiProject toCureParalysis, in a virus/antigen-free vivar-
iumwith a 12 h light/dark cycle, controlled temperature and humidity, and
were provided with water and food ad libitum. Mice were group caged
(maximum five per cage) throughout the duration of the experimentations.
Experiments were performed according to protocols and guidelines ap-
proved by the Institutional Animal Care andUse Committee of theUniver-
sity of Miami, and all efforts were made tominimize pain and distress.
Behavioral assessments
Open field test. The open field test was performed on adult male mice in
an odor-free, nontransparent square arena, as previously described
(Madsen et al., 2015). The arena was divided into three zones (wall,
intermediate, and center) andmouse behavior was recorded over a 5min
period using a high-resolution video camera. The total number of lines
crossed; the time spent in each zone; and stereotypical behaviors, such as
grooming and rearing, were analyzed and expressed as the number of
events. Mice that did not enter all three zones or cross a minimum of 50
lines during the 5 min trial were excluded.
Rotarod test. Motor coordination and balance were tested on the ac-
celerating rotarod cylinder (Rotamex 4/8, Columbus Instruments) in
adult male mice, as previously described (Madsen et al., 2015). The test
consisted of a 5 d pretraining (days 1–5) followed by the actual test
(day 7). The cylinder rotated at increasing speed and constant accelera-
tion (from 10 to 60 rpm over a 10 min period). The total time spent on
the rod before falling was recorded, and nonwalking behaviors, such as
passive clinging to the rod, were manually corrected for. Each trial con-
sisted of an average of 4 sessions. After each session, the mice were trans-
ferred back to their cage and allowed to rest for 20 min to avoid
exhaustion and minimize stress. Mice that could not maintain their bal-
ance on the rod for aminimumof 60 s during pretraining were excluded.
Induction of EAE
Active EAE was induced in 2-month-old female mice with MOG35–55
(BioSynthesis), as previously described (Brambilla et al., 2014). In select
experiments, mice were treated with XPro1595 (10mg/kg, s.c., every 3 d;
Xencor) or vehicle (0.9% saline). Behavioral assessments and drug ad-
ministration were conducted by a blinded investigator, as previously
described (Brambilla et al., 2014).
Immunohistochemistry
Mice were perfused with 0.1 M PBS followed by 4% paraformaldehyde
(PFA) in PBS. Spinal cord and brain were dissected out and postfixed for
2 h in 4% PFA. Tissues were cryoprotected in PBS plus 20% sucrose and
cutwith a cryostat into 30-m-thick serial sections. After blocking for 1 h
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with 5% normal goat serum in PBS plus 0.4% Triton-X, sections were
incubated overnight at 4°C with primary antibodies against APC (CC1
clone; 1:500; catalog #OP80, Millipore), NG2 (1:200; catalog #AB5320,
Millipore), PDGF receptor (PDGFR; 1:200; catalog #558774, BDBio-
science), Olig2 (1:500; #AB9610, Millipore), GFP (1:1000; catalog
#13970, Abcam), TNFR2 (1:50; catalog #SC-8041 and #SC-7862, Santa
Cruz Biotechnology). Immunoreactivity was visualized with secondary
species-specific fluorescent antibodies (1:750; Alexa Fluor-488, Alexa
Fluor-594, and Alexa Fluor-647, Invitrogen). Sections were coverslipped
with Vectashield mounting medium with DAPI (Vector Laboratories),
and imaged with an Olympus FluoView 1000 confocal microscope or
with a Zeiss Axiovert A1 fluorescence microscope.
Stereological quantifications
Five 30-m-thick serial sections taken at 300m intervals were analyzed
at a 63magnificationwith a Zeiss Axiovert A1 fluorescencemicroscope
by an investigator blinded to the genotype. The number of positive cells
per cubic millimeter of tissue was estimated with Stereo Investigator
software (MBF Bioscience) using the Optical Fractionator for unbiased
counting and systematic random sampling.
Toluidine blue analysis and electron microscopy
PFA-fixed 1 mm segments of the thoracic spinal cord were postfixed
overnight in 2% glutaraldehyde plus 100mM sucrose in 0.15 M phosphate
buffer, before incubation with 2% OsO4 for 1 h. Following dehydration
in graded ethanol solutions, tissues were embedded in epoxy resin
(Embed, ElectronMicroscopy Sciences). Semithin sections (1m thick)
were obtained with a Leica Ultracut E microtome and stained with 1%
toluidine blue solution. Samples were then examined by light micros-
copy. The number of toluidine blue-stained myelinated or degenerated
axons was estimated using Stereo Investigator software (MBF Biosci-
ence). From the same specimens, ultrathin sections (60–90 nm thick)
were cut for electronmicroscopy (EM) and imagedwith a Philips CM-10
transmission electron microscope.
Assessment of g-ratio and remyelination
EM micrographs of the spinal cord white matter were taken at a 5.2
thousand magnification (Brambilla et al., 2011). A grid was placed over
the section, and pictures were taken randomly from each quadrant. One
picture per quadrant was evaluated for a minimum of 25 images/mouse.
Fiber and axon diameter of each axonweremeasuredwith ImageJ. Axons
identified as “remyelinating” based on morphology (thin myelin, oligo-
dendrocyte cytoplasm between myelin and axolemma) were excluded
from the g-ratio analysis and counted as “remyelinating axons.” Quan-
tifications were conducted by a blinded investigator.
Cell isolation for flow cytometry
Following transcardial perfusionwith PBS, spinal cords and spleens were
harvested and placed in cold HBSS. Samples were mechanically disso-
ciated into single-cell suspensions through a 70 m cell strainer and
washed in HBSS. For leukocyte isolation from the spleen, suspensions
were spun at 400  g for 5 min, supernatants were removed, and red
blood cells were lysed in 2 ml of lysis buffer (eBioscience) according to
manufacturer instructions. Cells were then resuspended in flow cytom-
etry buffer (FCB; eBioscience) and stained as described below. Leuko-
cytes infiltrating into the spinal cordwere isolated bynegative selection of
single-cell spinal cord suspensionswithMyelinRemoval Beads II in com-
bination with LS columns, according to the manufacturer protocols
(Miltenyi Biotec). Similar to the spleen cells, spinal cord cells were resus-
pended in FCBand stained as described below. The number of viable cells
was determined by Trypan blue exclusion assay using a Bio-Rad TC20
automated cell counter.
Immunolabeling and flow cytometric analysis
Cells were resuspended in 100 l of FCB, blocked with 2 l of TruStain-
FcX (BioLegend) for 10min at 4°C and stained for 30min at 4°Cwith the
following antibodies: APC-Cy7-anti-CD45 (1:200; #103116, BioLeg-
end), FITC-anti-CD4 (1:200; catalog #11-0042, eBioscience), PerCP-
Cy5.5-anti-CD8a (1:200; catalog #100734, eBioscience), PE-Cy7-anti-
CD25 (1:200; catalog #25-0251-82, eBioscience), PE-anti-CD45R/B220
(1:200; catalog #103207, BioLegend), eFluor450-anti-CD11b (1:200; cat-
alog #48-0112-82, eBioscience), APC-anti-O4 (1:100; catalog #130-095-
891, Miltenyi Biotec), Alexa Fluor 488-anti-NG2 (1:200; catalog
#AB5320A4, Millipore), or PE-anti-CD120b (TNFR2; 1:200; catalog
#113406, BioLegend). Cell suspensions were then fixed and permeabil-
ized (mouse Foxp3 staining kit, eBioscience) before intracellular staining
with PE-anti-Foxp3 (1:100; catalog #12-5773-82, eBioscience). Cells
were resuspended in 500 l of FCB and analyzed with an LSRII flow
cytometer (BD Biosciences) equipped with FACS-Diva 6.0 software (BD
Biosciences).
RNA isolation and real-time PCR
Total RNA was extracted with TRIzol (Invitrogen) and reversed tran-
scribed as previously described (Brambilla et al., 2011). Real-time PCR
was performed in the Rotor-Gene 3000 Real Time Cycler (Corbett Life
Science) as described previously (Brambilla et al., 2011). Primers for gene
amplification are listed in Table 1. For miRNA amplification, following
TRIzol extraction, total RNA was purified with the miRNeasy Micro Kit
(Qiagen), then reverse transcribed with the Universal cDNA Synthesis
Kit II (Exiqon). cDNA diluted 1:10 to 1:100 (depending on the abun-
dance of the miRNA of interest) was amplified with the Power SYBR
Green PCR Master Mix (Invitrogen) with primers designed for U6 (ref-
erence miRNA for normalization), miR-7a, and miR-138 (Exiqon), ac-
cording to manufacturer recommendations. Quantitative PCR was
performed on an ABI 7300 Real-Time PCR System (ThermoFisher Sci-
entific). Relative miRNA expression was calculated using the Ct
method (Livak and Schmittgen, 2001) and expressed as a percentage of
WT oligodendrocyte precursor cell (OPC) miRNA expression.
Primary oligodendrocyte cultures
Cortices from postnatal day 4–6 pups were isolated and dissociated
into single cell suspensions with Papain Neural Tissue Dissociation Kit
(Miltenyi Biotec). PDGFR OPCs were isolated by MACS separation
using LS columns (Miltenyi Biotec) after incubation with PDGFR
magnetic microbeads. PDGFR cells were cultured on poly-D-lysine/
Table 1. Primers for real-time PCR gene amplification
Gene Primer sequence Product length
Optimal
Atemp
TNFR1 F: 5 gcccgaagtctactccatcatttg 3 91bp 56.2°C
R: 5 ggctggggagggggctggagttag 3
TNFR2 F: 5 gcccagccaaactccaagcatc 3 133bp 54.0°C
R: 5 tcctaacatcagcagacccagtg 3
CXCL10 F: 5 gccgtcattttctgcctcatcct 3 113bp 57.2°C
R: 5 ctcattctcactggcccgtcatc 3
IFN F: 5 aggaactggcaaaaggatggtgac 3 118bp 53.1°C
R: 5 tgacgcttatgttgttgctgatgg 3
TNF F: 5 aggcactcccccaaaagatg 3 123bp 56.6°C
R: 5 tcaccccgaagttcagtagacaga 3
IL-1 F: 5 cttcaaatctcacagcagcacatc 3 102bp 53.4°C
R: 5 ccacgggaaagacacaggtag 3
MBP F: 5 cggggctctggcaaggactcacac 3 101bp 54.3°C
R: 5 tggactactgggttttcatctt 3
PLP F: 5 ttccagaggccaacatcaag 3 149bp 54.4°C
R: 5 acacaggtacagccgagcag 3
GPR17 F: 5 atccctggctgtggcttttacctt 3 128bp 56.2°C
R: 5 caatcatgcggacggctttat 3
PDGFR F: 5 cctggcatgatggtcgattctact 3 134bp 55.3°C
R: 5 ggtctcttctcgggctcactgttc 3
Notch1 F: 5 gaggtcaacgagtgcaacagtaac 3 92bp 55.4°C
R: 5 ctccacccaggggcacagtcac 3
Jagged1 F: 5 tggcttgggtctgttgcttggtga 3 88bp 58.6°C
R: 5 tcgggggcggagtgagtgtgg 3
-actin F: 5 ctagacttcgagcaggagatgg 3 141bp 55.9°C
R: 5 caagaaggaaggctggaaaagag 3
GAPDH F: 5 gaggccggtgctgagtatgtcgtg 3 116bp 59.3°C
R: 5 tcggcagaaggggcggagatga 3
F, Forward; R, reverse; Atemp, Annealing temperature.
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laminin-coated 24-well plates (40,000 cells/well) in OPC medium con-
sisting of DMEM/F12/HEPES supplemented with 1% N2, 2% B27,
0.01% BSA, 7.5% NaHCO3, 1% penicillin/streptomycin, 10 ng/ml
PDGF-AA, and 10 ng/ml FGF2. After 2 d in culture 100% of DAPI cells
were positive for PDGFR and 97.5% positive for Olig2. No cells stained
for NeuN (neurons), GFAP (astrocytes), Iba1 (microglia), or PDGFR
(fibroblasts). Cells were maintained in OPC medium for 4 d. At day 4,
cells were either fixed/collected or switched to oligodendrocyte (OL)
differentiationmedium consisting ofDMEM/F12/HEPES supplemented
with 1% N2, 2% B27, 0.01% BSA, 7.5% NaHCO3, 0.5% gentamycin, 10
ng/ml CNTF, and 40 ng/ml T3. Cells were differentiated to premyelinat-
ing OLs for 4 d then fixed or collected for RNA extraction. OLs were
identified byO1 labeling of live cells with hybridoma culture supernatant
or MPB staining (rat, 1:500; catalog #MAB386, Millipore). Immunore-
activity was visualized with secondary species-specific fluorescent anti-
bodies (1:750; Alexa Fluor-594 and Alexa Fluor-488, Invitrogen).
Terminal deoxynucleotidyl transferase-mediated biotinylated
UTP nick end labeling staining
Apoptotic cell death was detected with the terminal deoxynucleotidyl
transferase-mediated biotinylatedUTP nick end labeling (TUNEL) assay
(Millipore) according to manufacturer protocols. Biotin-labeled frag-
mented DNA was visualized with strepdavidin-conjugated Alexa Fluor-
647 (1:2000; catalog #S-32357, Invitrogen). OPCs and OLs were
identified by double labeling with anti-PDGFR (rabbit; 1:200; catalog
#SC-338, Santa Cruz Biotechnology) and anti-APC (CC1 clone; mouse;
catalog #OP80, 1:500, Millipore), respectively, followed by Alexa Fluor-
488 goat anti-mouse secondary antibody (1:750; catalog #A11001,
Invitrogen). For each well, five images were acquired at a 20 magnifi-
cation, andPDGFRTUNEL andCC1TUNEL cells were counted
blindly.
Oligodendrocyte proliferation and differentiation by 5-ethynyl-2-
deoxyuridine incorporation
OPCs were incubated with 10 M 5-ethynyl-2-deoxyuridine (EdU) for
8 h at 37°C, either fixed with 4% PFA for 15 min at room temperature or
switched to OL medium, and differentiated for 4 d. EdU incorporation
was detected with the Click-iT EdU Alexa Fluor-594 Imaging Kit (Invit-
rogen) according to manufacturer protocols. OPC proliferation was as-
sessed as the ratio of PDGFREdU cells to total PDGFR cells. OL
differentiation was assessed as the ratio of CC1EdU cells to total
CC1 cells. Each condition was run in four replicates, and for each
replicate the cell number was determined as the average of five images
randomly collected. All images were recorded by a blinded investigator.
Data are the average SEM of three independent experiments.
MicroRNA expression
Spinal cords were harvested in cold HBSS and dissociated with Papain
Neural Dissociation Kit (Miltenyi Biotec). Single-cell suspensions were
cleared from myelin by incubation with Myelin Removal Beads II fol-
lowed by negative selection with LS columns (Miltenyi Biotec). To select
for cells of the oligodendrocyte lineage, suspensions were incubated
with 10 l of anti-PDGFR plus 10 l of anti-O4 magnetic microbeads
(Miltenyi Biotec) for 15 min at 4°C, then positively selected with LS
columns (Miltenyi Biotec). Cell viability and oligodendrocyte enrich-
ment were verified by flow cytometry using APC-anti-O4 (1:100; catalog
#130-095-891, Miltenyi Biotec) and PE-anti-PDGFR (1:100; catalog
#SC-338PE, Santa Cruz Biotechnology) antibodies, and the fraction of
PDGFR and O4 cells combined was assessed to be consistently
40% of the total number of viable cells. Total RNA was isolated with a
miRNeasy Kit (Qiagen), andmicroRNA expression was assayed with the
microRNA Ready-to-Use PCR Array (Mouse&Rat version 2.R; Exiqon).
Arrays were run on a LightCycler 480 real-time PCRmachine (Roche) at
the Oncogenomics Core Facility of the University of Miami. Data anal-
ysis was performed using the GenEx software (Multid Analyses AB). For
each comparison, output files from the LightCycler were uploaded to the
software and an interplate calibrationwas performed.Normalizationwas
performed using the global meanmethod (Mestdagh et al., 2009). Statis-
tical significance was assessed by an unpaired two-tailed t test.
In situ hybridization
Thirty-micrometer-thick isopropanol-fixed spinal cord sections were
subjected to standard in situ hybridization, as previously described, using
an alkaline phosphatase-labeled LNA probe recognizing mouse miR-7
(miR-7 probe: ACAACAAAATCACTAGTCTTCCA; DNA Technology
A/S; Hansen et al., 2013). Sections were rinsed 15 min in TBS plus 1%
Triton X-100 and incubated with anti-PDGFR antibody (1:250; catalog
#SC-338, Santa Cruz Biotechnology) in TBS plus 10% bovine serum
overnight, then incubated with Alexa Fluor-546 goat anti-rabbit IgG
(1:200; Invitrogen) for 1 h. Sections were mounted with Aquatex (EMD
Millipore). Expression ofmiR-7was visualizedwith bright-field imaging.
Colocalization with PDGFR immunostaining was determined after
conversion of the signal to green pseudocolor using Adobe Photoshop
software (Lambertsen et al., 2009). The number of miR-7a cells was
quantified in the intact white matter on spinal cord serial sections at 300
m intervals using ImageJ by an investigator blinded to the genotype.
Four to eight sections/mouse were analyzed, and numbers were normal-
ized to the area of intact white matter.
Statistical analysis
Statistical analysis of the clinical course of EAE was performed with the
Mann–Whitney U test. Histological data, flow cytometry assessments,
and real-time PCRwere analyzed by either one-way or two-way ANOVA
followed by Bonferroni’s or Tukey’s test formultiple comparisons. In the
case of single comparisons, the Student’s t test was applied. The g-ratio
data were analyzed by linear regression, and slope and elevation param-
eters were used to compare groups. p values0.05 were considered to be
statistically significant. Data were expressed as the average of multiple
determinations SEM. Statistical analyses were conducted with Graph-
Pad Prism software.
Results
Generation and characterization of CNP-cre:TNFR2fl/fl mice
To assess the pathophysiological function of oligodendroglial
TNFR2, we established CNP-cre:TNFR2fl/fl conditional KOs where
TNFR2 is ablated from OPCs and OLs. CNP-cre/mice (Lappe-
Siefke et al., 2003)were crossedwithTNFR2fl/flmutants obtainedby
breeding C57BL/6NTac-Tnfrsf1btm1a(EUCOMM)Wtsi/Ics mice with an
Flp1 deleter line to remove the FRT-flanked neomycin cassette (Fig.
1A,B). Recombination efficiency was evaluated by crossing CNP-
cre/micewithRosa26-stop-EYFP reportermice and determined
to be	60% inOPCs and close to 100% inOLs (Fig. 1C), indicating
that CNP-cre mice are suitable for TNFR2 ablation throughout the
lineage.TNFR2expression inNG2OPCsandO4OLswas found
to be significantly reduced in CNP-cre:TNFR2fl/fl mice by 	25%
and 40%, respectively (Fig. 1D). Stereological counting of
PDGFRTNFR2OPCs andCC1TNFR2OLs yielded similar
results (Fig. 1E,F). In addition,TNFR2gene expression in the spinal
cordwas downregulated comparedwith TNFR2fl/fl,WT, andCNP-
cre/mice (Fig. 1G). Importantly, oligodendroglial TNFR2 abla-
tion did not result in changes in the number of NG2PDGFR
OPCs (Fig. 1H) or CC1OLs (Fig. 1I,J), suggesting that TNFR2 is
not implicated in the regulation of oligodendrocyte survival and/or
maturation during development. To further investigate whether
TNFR2 ablationmight interferewith normal oligodendrocyte func-
tion,wequantified the expressionof genes involved in inflammation
andmyelination in the spinal cord and foundnodifference between
CNP-cre:TNFR2fl/fl mice and any of the control groups (Fig. 2A).
Finally, we assessed spontaneous activity and locomotor function
with the rotarod test (Fig. 2B,C) and open field test (Fig. 2D–I),
whereCNP-cre:TNFR2fl/flmiceperformedequally to controls.Typ-
ical and anxiety-related behaviors were not altered as well (Fig. 2E–
I).Collectively, thesedata indicate thatCNP-cre:TNFR2fl/flmice are
a suitable model to study oligodendroglial TNFR2 function in vivo.
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Ablation of oligodendroglial TNFR2 results in
EAE exacerbation
To assess whether oligodendroglial TNFR2 mediates tmTNF
protective function in neuroimmune disease, we induced EAE
with MOG35–55 peptide (Brambilla et al., 2014). CNP-cre:
TNFR2fl/fl mice showed a significantly worse clinical outcome
than TNFR2fl/fl controls, with earlier onset and exacerbated
chronic disease (Fig. 3A, Table 2). The administration of the
solTNF inhibitor XPro1595, which improved EAE in TNFR2fl/fl
controls in line with our previous studies (Brambilla et al., 2011),
Figure 1. Generation and characterization of CNP-cre:TNFR2 fl/fl mice. A, Schematic of the generation of CNP-cre:TNFR2 fl/fl mice: crossing of C57BL/6NTac-Tnfrsf1b tm1a(EUCOMM)Wtsi/Ics mice
carrying the targeted allele with Rosa26-Flp1mice to excise the neomycin resistance cassette; crossing of the resultingmice carrying the conditional allele with CNP-cre/mice to excise exons 2
and 3 of the TNFR2 gene and obtain mice carrying the KO allele. The WT allele is also depicted. B, Representative genotyping PCR on genomic DNA from litters of CNP-cre:TNFR2 fl/fl TNFR2 fl/fl
breeding pairs. C, Stereological counting of EYFPPDGFR and EYFPCC1 cells in the spinal cord of naive CNP-cre:Rosa26-stop-EYFP mice. Results are expressed as the percentage
EYFPPDGFR and EYFPCC1 cells of the total PDGFR and CC1 populations, respectively (n
 3/group).D, Flow cytometric assessment of NG2OPCs andO4OLs expressing TNFR2
in the spinal cord of TNFR2 fl/fl and CNP-cre:TNFR2 fl/fl naive mice. Data are expressed as the percentage SEM of the total NG2 or O4 population (n
 4–6/group). *p 0.05, Student’s t test. E,
Ratio of the number of PDGFRTNFR2 OPCs to the total number of PDGFR OPCs counted in the naive thoracic spinal cord by stereology (n
 4/group). *p 0.05, Student’s t test. F, Ratio
of thenumber of CC1TNFR2OLs to the total number of CC1OLs counted in thenaive thoracic spinal cordby stereology (n
4/group). *p0.05, Student’s t test.G, Assessment of TNFR2gene
expression in the naive spinal cord by real-time RT-PCR. Data are expressed as the percentage SEM ofWTmice (n
 4/group). *p 0.05, Student’s t test.H, Stereological quantification of the
total number of NG2PDGFR OPCs in the thoracic spinal cord in naive conditions (n
 3–5/group). I, J, Stereological quantification of the total number of CC1 OLs in the thoracic spinal cord
and in the corpus callosum, respectively, of naive mice (n
 4–5/group).
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did not show any benefit inCNP-cre:TNFR2fl/fl mice, confirming
that the therapeutic outcome of solTNF inhibition is dependent
on a functional TNFR2 in oligodendrocytes. Immune cell infil-
tration into the spinal cord mirrored the clinical course of the
disease. At peak EAE (19 dpi), CNP-cre:TNFR2fl/fl mice had a
significantly higher percentage of infiltrating CD4 and CD8T
cells, as well as a higher percentage of regulatory T cells (Fig. 3B).
By 25 dpi, when disease scores were almost overlapping, infiltrat-
ing cells were comparable between genotypes (Fig. 3C). In the
spleen, no differences were found in naive conditions or after
EAE (Fig. 3D–F). The acute phase of EAE was characterized by
the upregulation of proinflammatorymediators like TNF, IL-1,
IFN, and C-X-C ligand-10 (CXCL10; Fig. 3G), but no differ-
ences were found between CNP-cre:TNFR2fl/fl and TNFR2fl/fl
Figure 2. Ablation of oligodendroglial TNFR2 does not alter basal gene expression, locomotor function, or anxiety-like behaviors in naive conditions. A, Gene expression of inflammatory
molecules andoligodendrocyte-specific genesassessed in the spinal cordof CNP-cre:TNFR2 fl/flmice comparedwithWT, CNP-cre/, andTNFR2 fl/fl controls by real-timeRT-PCR.Dataareexpressed
as the percentage SEM ofWTmice (n
 4/group). One-way ANOVA, Tukey’s test.B, C, Assessment ofmotor coordinationwith the rotarod test: time spent on the rodwasmeasured during a 5 d
pretraining session (B) followed by the actual test (C; n
 7–16/group).D–I, Spontaneous activity and anxiety-like behaviors were evaluated with the open field test bymeasuring the number of
lines crossed (D), rearings (E), andgroomings (F ), and the time spent in thewall (G), inter (H ), and center (I ) zones (n
6–16/group). Nodifferenceswere observed amonggenotypes (by one-way
ANOVA with Tukey’s test).
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mice, likely due to the similar EAE severity at this stage of disease.
Interestingly, we found changes in the expression of TNF recep-
tors. TNFR2 was upregulated in TNFR2fl/fl mice after EAE but
not in CNP-cre:TNFR2fl/fl mice, which, as anticipated, showed
significant reduction of TNFR2 in naive as well as disease condi-
tions. TNFR1 was upregulated after EAE in both genotypes, but
with a higher increment in CNP-cre:TNFR2fl/fl mice. This could
be due to the increased infiltration of peripheral immune cells,
which are known to highly express TNFR1 (Vielhauer et al., 2005;
Liu and Tang, 2014).
Recent reports (Hagemeyer et al., 2012; Wieser et al., 2013)
have shown that CNP-cre/ mice display white matter abnor-
malities and axonal degeneration following aging or mild CNS
trauma. This is due to the CNPase loss of function resulting from
CNP-cre/mice having only one allele of the endogenousCnp1
gene (Lappe-Siefke et al., 2003), and this has highlighted the key
role of CNPase in myelin stability. Therefore, to exclude that
Cnp1 haploinsuffiency of the CNP-cre/ drivers could be re-
sponsible, at least in part, for the worsening of the clinical out-
come in CNP-cre:TNFR2fl/fl mice, we performed a control
experiment to assess the clinical course of EAE in CNP-cre/
versus WT mice. CNP-cre/ mice developed EAE similar to
controls (Fig. 3H) and showed comparable axonal damage
during chronic disease (Fig. 3I). This indicates that CNPase
loss of function is not a factor in EAE exacerbation in
CNP-cre:TNFR2fl/fl mice, which depends only upon TNFR2
ablation.
Ablation of oligodendroglial TNFR2 increases axonal loss
after EAE
To assess whether worsening of the clinical outcome in
CNP-cre:TNFR2fl/fl mice could be associated with more severe
axonal damage, we quantified the number of intact and degener-
ated axons in the spinal cord in naive conditions and chronic EAE
(Fig. 4A). No differences were found in naive mice, and with
chronic EAE both groups displayed widespread axonal loss and
accumulation of degenerated axons (Fig. 4A, black arrows). This
damage was further exacerbated in CNP-cre:TNFR2fl/fl mice,
who showed a significant reduction inmyelinated axons (Fig. 4B)
and an increase in degenerated axons (Fig. 4C). This suggests that
oligodendroglial TNFR2 plays a neuroprotective function in
pathological conditions.
Ablation of oligodendroglial TNFR2 increases myelin
pathology and reduces remyelination after EAE
Next, we investigated whether the increased axonal damage in
CNP-cre:TNFR2fl/fl mice was associated with worse oligoden-
drocyte and myelin pathology. We found a significant reduction
in the number of PDGFR OPCs in CNP-cre:TNFR2fl/fl mice
after EAE (Fig. 4D,E). CC1 OLs were also diminished com-
pared with naive mice (Fig. 4F,G), but the loss was significantly
higher in CNP-cre:TNFR2fl/fl mice (Fig. 4G), suggesting that oli-
godendroglial TNFR2 may play a role in the survival of existing
OLs and/or differentiation of OPCs into new OLs.
Myelin integrity in the spinal cord whitematter was examined
by EM.Morphologically, naive mice did not showmyelin abnor-
malities, but following EAE both genotypes displayed extensive
damage, with unraveling of the myelin sheaths, loss of adaxonal
contact, and complete demyelination in severe cases (Fig. 5A). To
measure myelin thickness, we assessed the g-ratio (axon diame-
ter/fiber diameter) of individual axons. We plotted the g-ratio
against the corresponding axon diameter and did not find any
difference in naive conditions by linear regression analysis (line
slope and elevation intercept on the y-axis were comparable; Fig.
5B). However, following EAE, CNP-cre:TNFR2fl/fl mice showed
significantly and consistently lower g-ratios compared with
TNFR2fl/fl controls, shown by reduced elevation of the linear
regression (CNP-cre:TNFR2fl/fl
 0.575 0.007 vs TNFR2fl/fl

0.615  0.005; p  0.0001, Student’s t test) without change in
slope (Fig. 5C). This was evident also by grouping axons by di-
ameter size, with the g-ratio significantly reduced after EAE in
CNP-cre:TNFR2fl/fl mice, except for axons of2 m (Fig. 5D).
This indicates that CNP-cre:TNFR2fl/fl mice have consistently
wider myelin rings compared with controls. It is important to
note that axons identified morphologically as undergoing remy-
elination (thin compact myelin, often with interposition of oli-
godendrocyte cytoplasmbetween axon and themyelin ring) were
not included in the g-ratio analysis, but were counted separately
for more accurate assessment of remyelination. Remyelinating
axons (Fig. 5E) were reduced in CNP-cre:TNFR2fl/fl mice com-
pared with TNFR2fl/fl controls (Fig. 5F), suggesting that TNFR2
in oligodendrocytes plays a role, directly or indirectly, in sustain-
ing the remyelination process.
TNFR2 regulates oligodendrocyte differentiation
To address whether oligodendroglial TNFR2 is involved in sur-
vival, proliferation, or differentiation ofOPCs andOLs, we estab-
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Figure 3. Ablation of oligodendroglial TNFR2 results in EAE exacerbation. A, Clinical course
of MOG35–55-induced EAE inmice treatedwith saline or XPro1595. Administration of XPro1595
(10 mg/kg, s.c., every 3 d) was initiated at day 16, when at least half the animals reached a
minimum score of 2. Results are expressed as the daily mean clinical score SEM of 6–11
mice/group from two experiments. The TNFR2 fl/fl curve is different from both the
CNP-cre:TNFR2 fl/fl and the TNFR2 fl/fl XPro1595 curves, and the latter is different from the
CNP-cre:TNFR2 fl/fl plus XPro1595 curve. *p  0.05, **p  0.01, one-way ANOVA, Mann–
Whitney test. B–F, Flow cytometric analysis of the leukocyte populations infiltrating into the
spinal cord or present in the spleen under naive and EAE conditions; n
 4–6/group, *p
0.05, **p 0.01, Student’s t test. G, Gene expression analysis of select molecules in the spinal
cord at 25 dpi EAE. Results are expressed as the percentage of TNFR2 fl/fl naivemice SEMafter
normalization to-actin gene expression; n
 4–6/group. *p 0.05, **p 0.01, one-way
ANOVA, Tukey’s test. H, Clinical course of MOG35–55-induced EAE in WT and CNP-cre
/mice
(n
 8/group). Curveswere compared by one-way ANOVA,Mann–Whitney test, and no differ-
ences were observed. I, Stereological quantification of toluidine blue-stained myelinated and
degenerated axons in semithin thoracic spinal cord sections at 50 dpi EAE (n
 3). No differ-
ences were found (Student’s t test).
Table 2. Clinical parameters of EAE
Group Incidence Onset (day)a Peak disease (score) Peak disease (d) CDI
TNFR2 fl/fl 90.9% (20/22) 15.42 0.62 3.19 0.22 18.00 1.09 100.10 17.75
CNP-cre:TNFR2 fl/fl 68.4% (13/19) 13.69 0.43* 3.64 0.07 17.43 0.72 142.20 11.33
TNFR2 fl/fl plus XPro1595 3.46 0.07 19.73 1.88 91.03 13.40
CNPcreTNFR2 fl/fl plus XPro1595 3.96 0.04** 19.00 0.58 160.80 6.10***
Data are reported as the mean SEM.
aDay of appearance of first clinical symptoms. CDI, cumulative disease index, calculated as the sum of the daily clinical scores beginning at onset.
*p 0.05 vs TNFR2 fl/fl; **p 0.001 vs TNFR2 fl/fl plus XPro1595; ***p 0.01 vs TNFR2 fl/fl plus XPro1595; Student’s t test.
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Figure4. Ablation of oligodendroglial TNFR2 results in increased axon and oligodendrocyte loss after EAE. A, Toluidine blue staining of semithin thoracic spinal cord sections from naive
and 60 dpi EAEmice. Black arrows indicate degenerated collapsed axons; scale bars, 25m. B, C, Stereological quantification of myelinated (B) and collapsed axons (C); n
 4 – 8/group.
*p 0.05, Student’s t test. D, F, Representative confocal images of PDGFR OPCs (D) and CC1Olig2 OLs (F) in the thoracic spinal cord of naive and 60 dpi EAE mice; scale bars, 10
m. E, G, Stereological quantification of PDGFR OPCs (E) and CC1 OLs (G); n
 4 –5/group. *p 0.05, ***p 0.001, Student’s t test.
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lished an in vitro system of WT and TNFR2/ OPC/OL cultu-
res. To assess TNFR2-dependent cell survival, we counted
PDGFRTUNELOPCsandCC1TUNELOLs,and foundno
difference betweenWT and TNFR2/ cells (Fig. 6A,C). The ratio
of PDGFRTUNEL cells to the total number of PDGFR
OPCsorCC1TUNEL cells to the total number ofCC1OLsdid
not vary (Fig. 6B,D), demonstrating that TNFR2 is not required for
OPCorOLsurvival in vitro.Nevertheless, the totalnumberofCC1
OLswas significantly reduced in TNFR2/ cells (Fig. 6C), suggest-
ing that TNFR2 could bemodulating OPC proliferation, differenti-
ation, or both. To assess proliferation, OPCs were incubated with
EdU and fixed 8 h later. We found no difference between WT and
TNFR2/OPCs in the number of PDGFREdU actively pro-
liferating cells (Fig. 6E), and the ratios of PDGFREdU to total
PDGFR cells were similar (Fig. 6F). To assess OPC differentia-
tion, 8 h after the addition of EdU cells were switched to differenti-
ationmediumand fixed4d later.WecountedCC1EdUOLsand
found that a reduced number of EdU-incorporatingOPCs differen-
tiated intoOLs inTNFR2/ cultures comparedwithWT(Fig. 6E).
This was also shown by the lower ratio of CC1EdU cells to
PDGFREdU cells (Fig. 6G), indicating that TNFR2 is impor-
tant for OPC differentiation but not proliferation. The reduced
differentiation capability of cells lackingTNFR2was furtherdemon-
strated by immunocytochemistry in differentiated cultures (Fig.
6H). WT cells showed highly differentiated flat morphology, with
diffusedO1 andMBP immunoreactivity. TNFR2/ cells appeared
immature, with thin elongated processes, small cell body, and re-
duced MBP immunoreactivity. Impaired differentiation was also
demonstrated by gene expression analysis (Fig. 6I), with PDGFR
significantlyhigher inTNFR2/OLsandnotdifferent fromundif-
ferentiated OPCs, MBP drastically reduced in TNFR2/OLs, and
notch1, which acts as a brake toOPCdifferentiation (Juryn´czyk and
Selmaj, 2010), elevated in TNFR2/OPCs. Collectively, these data
demonstrate that TNFR2 drives OPC differentiation but does not
regulate OPC survival or proliferation.
Figure5. Ablationof oligodendroglial TNFR2 results in impairedmyelin compactionand reduced remyelinationafter EAE.A, Electronmicrographsof the lateral columnsof the thoracic spinal cord
comparing TNFR2 fl/fl to CNP-cre:TNFR2 fl/fl mice in naive conditions and 60 dpi EAE. Scale bar, 2m. B, C, Representation of the g-ratio (axon diameter/fiber diameter) vs the corresponding axon
diameter in naive conditions (B) and at 60 dpi EAE (C).D, Quantification of the g-ratios ofmyelinated fibers grouped by increasing axon diameter; n
 4–5/group. *p 0.05, **p 0.01, ***p
0.001, one-way ANOVA, Tukey’s test. E, Electron micrographs of remyelinating axons (black arrows) in the thoracic spinal cord of TNFR2 fl/fl mice at 60 dpi. Scale bar, 1m. F, Quantification of
remyelinating axons in naive conditions and at 60 dpi EAE; n
 4–5/group. *p 0.05, Student’s t test.
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Figure 6. TNFR2 regulates OPC differentiation, but not proliferation or survival in vitro. A, Cell death analysis by TUNEL staining in OPC cultures fromWT and TNFR2/mice (day 4 in culture).
Results are the average SEM of five replicates/experiment from three experiments. B, Ratio of PDGFRTUNEL cells to the total number of PDGFR cells as ameasure of OPC cell death. C,
Cell death analysis by TUNEL staining in differentiated OL cultures fromWT and TNFR2/mice (4 d in differentiation medium). Results are the average SEM of five (Figure legend continues.)
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Ablation of oligodendroglial TNFR2 dysregulates
miRNA expression
To address the mechanisms of TNFR2-dependent regulation of
OPC differentiation, we investigated changes in miRNA expres-
sion in the spinal cord of TNFR2fl/fl andCNP-cre:TNFR2fl/flmice
in naive and 25 dpi EAE conditions. Since miRNAs are known to
regulate oligodendrocyte differentiation (Dugas et al., 2010; Zhao
et al., 2010;He et al., 2012), and canmodulate or bemodulated by
TNF signaling (Sua´rez et al., 2010; Chen et al., 2014), we quanti-
fied miRNA expression in oligodendrocyte-enriched spinal cord
suspensions. In naivemice, we found differential expression of 29
miRNAs (Table 3). Most notably, miR-7a, which has been impli-
cated in arresting oligodendrocyte differentiation (Zhao et al.,
2012), was increased by 3.58-fold in CNP-cre:TNFR2fl/fl mice
compared with TNFR2fl/fl mice. After EAE, we saw differential
expression of 10 miRNAs in CNP-cre:TNFR2fl/fl mice compared
with TNFR2fl/fl controls (Table 3). Interestingly, inflammatory
miR-326, reportedly associated with MS and EAE pathogenesis
by promoting Th17 differentiation (Du et al., 2009; Honardoost
et al., 2014), was upregulated in CNP-cre:TNFR2fl/fl mice.
As anticipated, we found a large number ofmiRNAs altered as
a consequence of EAE within each genotype. Nevertheless, when
we focused on those involved in OPC differentiation and myeli-
nation (Table 4), we found different expression patterns in
TNFR2fl/fl and CNP-cre:TNFR2fl/fl mice. Two members of the
miR-219 andmiR-138 clusters, andmiR-338–5p, all required for
oligodendrocyte differentiation (Dugas et al., 2010; Zhao et al.,
2010; de Faria et al., 2012; Pusic and Kraig, 2015), were down-
regulated in CNP-cre:TNFR2fl/fl mice, but not in TNFR2fl/fl
controls, suggesting that oligodendroglial TNFR2 may be regu-
lating OPC differentiation in disease conditions via modula-
tion of these molecules. Similarly, miR-7a changed only in
CNP-cre:TNFR2fl/fl mice with significant downregulation after
EAE. Since miR-7a showed the highest differential expression in
naive conditions (Table 3), we further investigated whether it
played a direct role in the protective function of oligodendroglial
TNFR2 in EAE. We quantified miR-7a expression in vivo by in
situ hybridization in naive and 25 dpi EAE conditions, when the
peak of the inflammatory response is over and the repair process
is underway. In agreement with previous studies localizing
miR-7a in the CNS mainly in OPCs (Zhao et al., 2012), in the
spinal cord white matter we found miR-7a to be almost exclu-
sively expressed in PDGFR OPCs (Fig. 7A). The number of
miR-7a cells in the intact white matter was significantly in-
creased in CNP-cre:TNFR2fl/fl mice compared with TNFR2fl/fl
controls in naive conditions (Fig. 7B), mirroring the PCR array
data (Table 3). However, at 25 dpi EAE expression reversed, with
a significant reduction in the number miR-7a cells in
CNP-cre:TNFR2fl/fl mice (Fig. 7B). To better understand
whether TNFR2 could be directly modulating miR-7a within the
oligodendrocyte population during differentiation, wemeasured
miR-7a expression by real-time PCR in OPCs and OLs fromWT
and TNFR2/ mice. Unlike the EAE condition in vivo where
oligodendrocytes are exposed to a highly proinflammatory envi-
ronment, in vitro we tested miR-7a expression in nonstimulated
conditions. In WT cultures, miR-7a expression dropped as cells
differentiated to the OL stage (Fig. 7C). However, in the absence
of TNFR2, miR-7a stayed elevated at the OL stage (Fig. 7C) and
coincided with the failure of cell maturation (Fig. 6H, I). In line
with the report by Zhao et al. (2012) showing that blockade of
miR-7a in differentiating neural progenitors leads to reduced OL
4
(Figure legend continued.) replicates/experiment from three independent experiments.
*p 0.05, Student’s t test.D, Ratio of CC1TUNEL cells over total CC1 cells asmeasure of
OL cell death. E, Assessment of OPC proliferation/differentiation by EdU incorporation in OPC
cultures from WT and TNFR2/ mice: PDGFREdU OPCs are counted 8 h after EdU
administration, and OPCs that have differentiated into OLs are counted as CC1EdU cells 4 d
later after switching to differentiation medium. Results are the average SEM of four repli-
cates/experiment from three independent experiments. *p 0.05, Student’s t test. F, Ratio of
PDGFREdU cells over total PDGFR cells as a measure of OPC proliferation. G, Ratio of
CC1EdU cells over PDGFREdU cells as a measure of OPC differentiation. *p 0.05,
Student’s t test.H, Qualitative immunocytochemical comparison of differentiated OLs fromWT
and TNFR2/ mice stained with O1 (mature OL marker) and MBP (premyelinating OL
marker). I, Gene expression analysis ofmolecules involved in oligodendrocyte differentiation in
OPCs and OLs fromWT and TNFR2/mice.
Table 3. Differential microRNA expression in oligodendrocyte-enriched spinal cord
suspensions: comparison between genotypes
microRNA
CNP-cre:TNFR2 fl/fl
naive vs TNFR2 fl/fl
naive (fold change) p value
CNP-cre:TNFR2 fl/fl
EAE vs TNFR2 fl/fl
EAE (fold change) p value
mmu-miR-7a 3.5822 0.0264
mmu-miR-451 3.5698 0.0169
mmu-miR-2145 3.3904 0.0074
mmu-miR-100 3.3423 0.0381
mmu-miR-1937a 3.2336 0.0434
UniSp6 CP 2.9966 0.0245
mmu-miR-10b 1.9230 0.0152
mmu-miR-486 1.7331 0.0498
mmu-let-7e 1.6945 0.0161
rno-miR-29b-2 1.3659 0.0224
mmu-let-7f 1.3203 0.0308
mmu-miR-320 1.3021 0.0402
mmu-miR-425 1.2864 0.0264
mmu-miR-99b 1.1454 0.0212
mmu-miR-221 1.1414 0.0055
rno-miR-345-5p 1.2198 0.0066
rno-miR-382 1.2645 0.0181
mmu-miR-30b 1.2738 0.0055
mmu-miR-669d 1.3227 0.0145
mmu-miR-488 1.3488 0.0410
rno-miR-324-3p 1.4325 0.0022
mmu-miR-326 1.5493 0.0452
rno-miR-551b 1.5628 0.0151
mmu-miR-218-2 1.5712 0.0210
mmu-miR-551b 1.5764 0.0328
mmu-miR-467b 1.7221 0.0161
mmu-miR-192 1.7583 0.0012
rno-miR-136 1.8361 0.0254
mmu-miR-22 1.9174 0.0053
mmu-let-7e 1.9980 0.0321
mmu-miR-669e 2.0235 0.0199
mmu-miR-190 2.2025 0.0103
mmu-miR-362-3p 2.3321 0.0015
mmu-miR-96 2.3524 0.0010
mmu-miR-28 2.3705 0.0316
mmu-miR-669l 3.0459 0.0415
mmu-miR-673-5p 2.4667 0.0427
mmu-miR-198 2.3729 0.0165
mmu-miR-1274a 1.7736 0.0230
mmu-miR-326 1.4866 0.0177
mmu-miR-34a 1.4484 0.0418
mmu-miR-669d 1.4473 0.0083
mmu-miR-101a 1.3692 0.0500
mmu-miR-421 1.2466 0.0210
mmu-miR-130b 1.7654 0.0434
mmu-miR-322 1.7818 0.0165
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numbers, our data suggest that TNFR2 may drive OPC differen-
tiation at least in part by repressing miR-7a function.
We also tested in vitro the expression of miR-138, which we
found differentially regulated in our microRNA screening after
EAE (Table 3). miR-138 was significantly higher in TNFR2/
OPCs compared with WT cells (Fig. 6C). In differentiated OLs,
expression was increased with no difference between WT and
TNFR2/ cells (Fig. 7C). This suggests thatmiR-138, an impor-
tant signal in oligodendrocyte differentiation, is likely not regu-
lated by TNFR2.
Discussion
Using new oligodendrocyte-specific TNFR2 conditional KO
mice in combination with the solTNF inhibitor XPro1595, we
demonstrate that TNFR2 expressed in the oligodendrocyte lin-
eage contributes to tmTNF-mediated beneficial effects in EAE,
providing the first direct in vivo evidence that oligodendroglial
TNFR2 is protective in neuroimmune disease. We previously
demonstrated that tmTNF signaling is necessary for functional
recovery, axon preservation, and remyelination in EAE (Bram-
billa et al., 2011), and here we address themolecular mechanisms
of this effect by showing they depend, at least in part, on direct
activation of TNFR2 in oligodendrocytes. Aside from a study by
Arnett et al. (2001) in whole-animal TNFR2/mice suggesting
a protective role for TNFR2 in demyelination, and a study by
Maier et al. (2013) reporting that the activation of TNFR2 in
OPCs is protective against oxidative stress, the function of oligo-
dendroglial TNFR2 is largely unknown. With the generation of
CNP-cre:TNFR2fl/fl mice, we were able to directly investigate the
biological function of oligodendroglial TNFR2 both in normal
and pathological conditions. Under naive conditions, ablation of
TNFR2 did not alter oligodendrocyte cell number or impair lo-
comotor function and spontaneous activity, indicating that
TNFR2 is not implicated in the regulation of oligodendroglial
function during development. After EAE, however, TNFR2 abla-
tion resulted in a worsening of the clinical outcome that was not
rescued by treatment with XPro1595. This indicates that tmTNF-
mediated beneficial effects require the presence of TNFR2 in oli-
godendrocytes. It also underscores that worsening of the EAE
outcome in CNP-cre:TNFR2fl/fl mice cannot simply be attrib-
uted to an “unmasking” of TNFR1 detrimental function. If that
was the case, XPro1595 would be effective in protecting mice
from EAE, because it selectively inhibits solTNF, which activates
TNFR1.
In CNP-cre:TNFR2fl/fl mice, EAE symptoms manifested ear-
lier and weremore severe than in control mice at chronic disease.
This suggests that oligodendroglial TNFR2 likely contributes to
protection from EAE via multiple mechanisms: it may serve as
anti-inflammatory signal, hence affecting the onset of the disease;
and may provide signals benefitting axon and myelin integrity,
thereby affecting the chronic phase of the pathology. The notion
that oligodendroglial TNFR2 may be implicated in suppressing
the inflammatory response is supported by two lines of evidence:
first, CNP-cre:TNFR2fl/fl mice showed a higher percentage of
infiltrating CD4 and CD8 T cells at peak disease; and, second,
proinflammatory miRNAs were found to be upregulated in
CNP-cre:TNFR2fl/fl mice at the acute stage of disease. The most
notable example is miR-326, which has been linked to MS and
EAE pathogenesis as a promoter of Th17 differentiation (Du et
al., 2009; Honardoost et al., 2014). miR-326 has been found up-
regulated in the blood of patients undergoing relapse (Honar-
doost et al., 2014) and diminished after natalizumab treatment
(Ingwersen et al., 2015).Whether the anti-inflammatory effect of
oligodendroglial TNFR2 occurs directly in oligodendrocytes or
indirectly via other cell populations remains to be seen. Regard-
less, our data highlight that oligodendrocytes have functions that
go beyond myelination, repair, and metabolic support of neu-
rons, which is in tune with the roles of the other glial cell popu-
lations. TNFR2 activation inmicroglia has been shown to induce
the production of the neuroprotective molecules granulocyte
colony-stimulating factor, adrenomedullin, and IL-10 (Veroni et
al., 2010). Hence, we can speculate that a similarmechanismmay
be at play in oligodendrocytes, and the reduced production of
anti-inflammatory signals in CNP-cre:TNFR2fl/fl mice may ex-
plain the greater influx of encephalitogenic T cells into the CNS.
Ultimately, a better understanding of the role of oligodendroglial
TNFR2 in inflammation is important to have a complete picture
of the function of this receptor in neuroimmune disease, and this
is the focus of ongoing studies in our laboratory.
In addition to an anti-inflammatory function, our data point to
an effect of oligodendroglial TNFR2 in neuroprotection, myelin
repair, and remyelination. Indeed, the ablation of TNFR2 in
CNP-cre:TNFR2fl/fl mice resulted in increased axonal loss and my-
elin damage, as well as reduced remyelination. The reduced g-ratios
measured in CNP-cre:TNFR2fl/fl mice indicate the presence of
thicker myelin rings. Because it is unlikely that this depends on oli-
godendrocytes producing more myelin and wrapping more layers
around the axons, it is plausible that thicker rings are the conse-
quence of a loss of myelin compaction and/or axonal atrophy, sug-
gesting that TNFR2 plays a role in the maintenance of myelin and
axon integrity in disease conditions. In the absence of oligodendro-
glial TNFR2, the pool of OPCs was drastically depleted following
EAE, and in vitro experiments demonstrated thatTNFR2 is required
for OPC differentiation. This is significant because efficient OPC
differentiation is the prerequisite for repair in demyelinating pathol-
ogies (Kremer et al., 2015). Failure of this process prevents remyeli-
nation, leading to axonal damage and ultimately to neuronal loss,
which is the cause of permanent disability inMS.While reports have
shown that TNFR2 in astrocytes (Patel et al., 2012; Fischer et al.,
2014) may activate cascades that indirectly stimulate OPC differen-
tiation, here we show for the first time that direct TNFR2 activation
in OPCs is crucial in promoting differentiation, thereby sustaining
the remyelination process. We did not observe a developmental
impairment of OPC differentiation in vivo, because oligodend-
rocytes numberswere comparable innaiveTNFR2fl/fl andCNP-cre:
TNFR2fl/fl mice. This apparent contradiction with our in vitro data
can be reconciled in twoways. First, CNP-cremice allow for TNFR2
Table 4. Expression of microRNAs controlling oligodendrocyte differentiation and
myelination: comparison within genotype
microRNA
CNP-cre:TNFR2 fl/fl
EAE vs CNP-cre:TNFR2 fl/fl
naive (fold change) p value
TNFR2 fl/fl EAE
vs TNFR2 fl/fl
naive (fold change) p value
mmu-miR-146a 66.6901 0.0000002 123.7152 0.00001
mmu-miR-17 10.2789 0.0036821 17.7639 0.00214
mmu-miR-19b 9.0750 0.0005313 7.5600 0.00043
mmu-miR-23a No difference 5.7294 0.00152
mmu-miR-9 No difference 2.4227 0.00871
mmu-miR-338-3p No difference 3.1473 0.02190
mmu-miR-338-5p 4.3925 0.0406403 No difference
mmu-miR-7a-1 1.3028 0.0205852 No difference
mmu-miR-7a 3.5018 0.0272708 No difference
mmu-miR-138-1 2.6980 0.0201186 No difference
mmu-miR-138 7.9068 0.0031193 No difference
mmu-miR-219-5p 2.4084 0.0147652 No difference
mmu-miR-219-3p 11.3797 0.0153228 No difference
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ablation in40% of OPCs, and this may not translate into a devel-
opmental phenotype.Better suited to addressOPCdifferentiation in
vivo are PDGFR-creER drivers, where recombination is highly effi-
cient and specific in OPCs. Experiments with this mouse line are
currently ongoing in the laboratory. Second, unlike the in vitro
model where purified OPCs do not receive inputs from other cell
types, OPC differentiation in vivo is controlled by the concerted ac-
tion of numerous environmental signals converging on the OPCs.
Therefore, it is likely that othermechanisms compensate for TNFR2
absence, allowing for normal OPC differentiation.
The cascades initiated by TNFR2 to drive differentiation in-
clude themodulation ofmiRNAs, such asmiR-7a. It was recently
reported that the overexpression of miR-7a in OPCs promotes
proliferation and inhibits differentiation into a mature OL phe-
notype (Zhao et al., 2012), and overexpression in retinal glial
precursors reduces the differentiation of Mu¨ller glia (Baba et al.,
2015). Additionally, in adult rats it has been shown that miR-7a
expression is downregulated inmatureOLs comparedwithOPCs
(Lau et al., 2008). Our expression data, both from PCR array and
in situ hybridization, show that in the absence of oligodendroglial
TNFR2 miR-7a expression in the spinal cord white matter is
elevated under naive conditions. Since we found almost exclusive
expression of miR-7a in PDGFROPCs in the white matter, in
agreement with previous reports (Zhao et al., 2012), this suggests
a direct regulation of miR-7a expression in OPCs by TNFR2.
Furthermore, because we showed that OPCs and OLs do not
change in numbers in naive conditions when TNFR2 is ablated,
this suggests that TNFR2-dependent modulation of miR-7a in
oligodendrocytes does not play a role during development. We
could speculate that this mechanism might be important only
after injury to the CNS, such as in EAE, when TNFR2 expression
is upregulated in all glial populations, including oligodendro-
cytes. After EAE, the lack of oligodendroglial TNFR2 results in
reduced numbers of miR-7a-expressing cells in the white matter
(mostly OPCs). This may depend on the higher OPC loss seen in
CNP-creTNFR2fl/fl mice, but it may also be an adaptive response
in an attempt to boost OPC differentiation to sustain the repair
and remyelination process. In vitro, in noninflammatory condi-
tions, we showed that the drop in miR-7a expression occurring
whenOPCs transition toOLs does not take place in the absence of
TNFR2, demonstrating that TNFR2 directly regulates miR-7a.
Nevertheless, we cannot exclude that oligodendroglial TNFR2
might also be modulating miR-7a expression indirectly.
In addition tomiR-7a, others known to regulateoligodendrocyte
differentiation were found to be dysregulated as a consequence of
TNFR2 ablation, specificallymembers of themiR-219 andmiR-138
clusters, as well as miR-338–5p. All of these miRNAs are highly
expressed in the spinal cord, and some are required for normal oli-
Figure7. Oligodendroglial TNFR2modulatesmiR-7aexpression in the spinal cordwhitematter.A, ExpressionofmiR-7aby in situhybridization innaive CNP-cre:TNFR2 fl/flmice and colocalization
with PDGFROPCs (immunohistochemically labeled) in the spinal cordwhitematter. Scale bars: lowermagnification, left panel, 50m;highermagnification, right panel, 10m.White arrows,
Examples of OPCs positive formiR-7a.B, Quantification of the number ofmiR-7a cells in the intact spinal cordwhitematter in naive and EAE conditions (n
 4/group). *p 0.05, ***p 0.001,
one-way ANOVA, Bonferroni’s test. C, Quantification of miR-7a andmiR-138 expression by real-time PCR in OPCs and OLs fromWT and TNFR2/mice; n
 4. #p 0.05, Student’s t test; *p
0.05, **p 0.01, one-way ANOVA, Tukey’s test.
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godendrocyte differentiation and myelination in both rodents and
humans (Dugas et al., 2010; Zhao et al., 2010; de Faria et al., 2012).
We found these molecules to be highly downregulated after EAE in
CNP-cre:TNFR2fl/fl mice, but not in TNFR2fl/fl mice, providing yet
another indication that TNFR2 is necessary for activating OPC dif-
ferentiation programs without which remyelination cannot effec-
tively take place.
In summary, our study provides the first direct evidence that
TNFR2 is an important signal for oligodendrocyte differentia-
tion. Following activation by tmTNF, TNFR2 initiates specific
pathways, which include miRNA modulation, that drive oligo-
dendrocytes into a reparative mode contributing to remyelina-
tion following disease, thereby preventing axonal loss and
disability. This identifies TNFR2 as a viable new therapeutic tar-
get in neuroimmune disease. Selective TNFR2 agonists and selec-
tive solTNF inhibitors, which skew the balance toward TNFR2
activation, could be used separately or in combination to pro-
mote myelin repair. This may represent a new, much-needed
pharmacological tool for the primary progressive form of MS
where disability is directly dependent on irreparable axonal dam-
age associated with demyelination and for which no effective
treatments are available.
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